Press Releases

OS Therapies, Inc., a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, today announced positive data from a Phase 1 clinical trial of OST-HER2 in patients with HER2-expressing solid tumors in breast cancer and other cancers. Additionally, the Company announced positive preclinical efficacy data for OST-HER2 in multiple models of breast cancer. The FDA has granted Rare Pediatric Disease Designat

Read more...

OSE Immunotherapeutics SA, today announced positive topline results from its Phase 2 CoTikiS randomized, double-blind, placebo-controlled proof-of-concept study with Lusvertikimab, a pure IL-7 receptor antagonist, demonstrating significant efficacy results as measured by improvement in Modified Mayo Score** (at Week 10, the primary endpoint of the induction phase of treatment). A favorable safety profile was observed during both the induction phase and the 6-month open-label extension phase o

Read more...

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in clinical trial of the Company's novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 in the United States. ICP-332 is a potent and selective TYK2 inhibitor. ICP-332 achieved multiple efficacy endpoints in the China Phase II study for the treatment of patients with moderate-to-severe atopic dermatitis (AD), demonstr

Read more...

 Xavo, a leading provider of innovative software solutions for Life Sciences R&D, proudly announces Plexium as its latest esteemed client. - “We are thrilled to welcome Plexium to the Xavo family. The collaboration between the two companies marks a significant milestone in Xavo’s journey. We stay committed to deliver cutting-edge technology, tailored to meet the evolving needs of R&D labs worldwide,” says Gabriel Petrescu, Xavo’s VP of Business Dev

Read more...

Currax Pharmaceuticals LLC today announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA). The new site doubles the current production capacity of CONTRAVE/MYSIMBA and ensures continuity of supply, and the site has capacity to increase production when needed. An application to the U.S. Food & Drug Administration (FDA) for approval of this additional site is scheduled for Q3 2024. As

Read more...

Touchlight, an innovation-driven CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced a license agreement with GSK, a global leader in biopharmaceutical innovation. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA™ (doggybone DNA™) technology for the development and production of mRNA-based products. The license will enable GSK to access the leading technology for rapid and

Read more...

CannaMore Biotechs, an Israel-based clinical-stage company focused on Cannabidiol (CBD) based treatments, is pleased to announce the successful completion of its Phase 2a clinical trial evaluating the safety and efficacy of a CBD-based patent protected formulation for patients with Ulcerative Colitis (UC). The trial is an open-label, single-arm study, aimed to assess the safety, tolerability, and efficacy of the CBD-based IP-based enema formulation, IcBD-01, as a potential treatment

Read more...

Rusan Pharma Private Limited, a pharmaceutical company based in India specializing in the area of addiction treatment and pain management, recently announced that the United States Food and Drug Administration (USFDA) has granted Good Manufacturing Practice (GMP) approval for its Active Pharmaceutical Ingredient (API) facility in Ankleshwar (Gujarat, India). This milestone marks a significant achievement for the company as it paves the way for it to enter the US API market. With an

Read more...